Ibuprofen API Market Share

APAC Market Forecast

The Asia Pacific ibuprofen API market is set to generate the highest share of about 35% during the forecast period. This growth is set to be influenced by the low manufacturing cost of manufacturing medicines. India and China and two important nations which carry the least manufacturing cost in this region. Furthermore, this region is also experiencing a rise in health expenditure. The healthcare benefit cost trends in APAC increased from an average of over 5% in 2020 to close to 8% in 2021 before dropping to over 6% in 2022. It was anticipated that costs would increase to approximately 11% in 2023 from the previous year. Hence, all these factors are predicted to encourage the ibuprofen API market share in this region.

North American Market Analysis

The North America ibuprofen API market is also projected to have notable growth during the forecast timeframe. This growth of the region’s market is set to be influenced by the rising prevalence of migraine. North America’s population rigorously follows a sedentary lifestyle because of which the prevalence of migraine might be high among them. In the US, ibuprofen has been an over-the-counter (OTC) drug for 25 years. It is an effective and well-tolerated NSAID. Compared to many prescription therapies, over-the-counter (OTC) drugs are more accessible, less expensive, and have better safety profiles. Ibuprofen is a compelling option for over-the-counter management of migraine headaches. As a result, the ibuprofen API market is growing in this region.